Mizuho Markets Americas LLC Takes $17.14 Million Position in Zoetis Inc. $ZTS

Mizuho Markets Americas LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 136,250 shares of the company’s stock, valued at approximately $17,143,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Lloyd Advisory Services LLC. purchased a new position in Zoetis during the fourth quarter valued at approximately $65,000. Advisory Alpha LLC grew its stake in Zoetis by 2.7% during the fourth quarter. Advisory Alpha LLC now owns 4,578 shares of the company’s stock valued at $576,000 after acquiring an additional 122 shares in the last quarter. Vantage Investment Partners LLC grew its stake in Zoetis by 28.8% during the fourth quarter. Vantage Investment Partners LLC now owns 99,292 shares of the company’s stock valued at $12,493,000 after acquiring an additional 22,189 shares in the last quarter. Kingdom Financial Group LLC. purchased a new position in Zoetis during the fourth quarter valued at approximately $41,000. Finally, Diamond Hill Capital Management Inc. grew its stake in Zoetis by 17.3% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,158,638 shares of the company’s stock valued at $397,420,000 after acquiring an additional 465,839 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 11,650 shares of company stock valued at $886,384 in the last quarter. Corporate insiders own 0.22% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Friday. Finally, UBS Group reduced their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $133.92.

Zoetis Price Performance

ZTS stock opened at $81.26 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23. The stock has a market cap of $34.06 billion, a PE ratio of 13.48, a P/E/G ratio of 1.31 and a beta of 0.87. The firm has a 50 day simple moving average of $108.11 and a two-hundred day simple moving average of $118.65.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the prior year, the firm earned $1.48 EPS. Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.